03

January 3, 2018

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Astaxanthin, Epicatechin and Matrine (AEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/January/2018, 9.55 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
January 3, 2018

Vitamin-based therapy for Metabolic diseases: A pharmaceutical mixture [PMFA] encompassing Pyridoxamine(PM) and Folic acid (FA) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 3/January/2017, 9.43 am

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June […]
January 3, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM:Docosahexaenoic acid (DHA) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 3/January/2017, 9.34 am

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
January 3, 2018

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Geldanamycin, 5-Azacitidine, Temozolomide, Cerivastatin, Salinomycin, &, Fluoxetine (GATCSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 3/January/2018, 9.23 am

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer […]